Skip to main content

Implementation plan

 

What we will achieve How we will achieve it
Less stigma and discrimination
  • Work with partners to assess emerging evidence and promote strategies to reduce the impacts of stigma and discrimination in the lives of people affected by hepatitis B and hepatitis C.

  • Build coalitions with others working to reduce stigma and discrimination related to hepatitis B and hepatitis C in healthcare and other settings.
A stronger workforce
  • Create opportunities for shared learning for staff across members including through CEO forums, communities of practice and one-off and periodic events.

  • Establish a workforce development program for members and community partners including continuous learning and skills development that enhances knowledge, practice and impact.

  • Include within the workforce development program learning for new community workers on foundational knowledge in viral hepatitis.
Better evidence and research
  • Co-create with researchers, members and people with lived experience of hepatitis B and hepatitis C an agenda for strategic and investigator-driven research.

  • Position Hepatitis Australia as the go-to partner for research that drives innovation and identify new ways to translate research to community and health settings.

  • Work with researchers to establish a clearer profile of hepatitis B and hepatitis C within Australia’s culturally and linguistically diverse communities and guide members on what this means for programming.

  • Advocate for improved completeness of Aboriginal and Torres Strait Islander identifiers in notification data for viral hepatitis.

  • Advocate for the mandatory recording of hepatitis B birth dose administration in the Australian Immunisation Register (AIR).

  • Work with researchers to promote data linkage that addresses research and surveillance gaps.
Innovation
  • Monitor the global evidence base and promote innovation that places Australia at the cutting edge of policy and practice.

  • Explore opportunities and manage the risks of artificial intelligence and new technologies for members and communities.

  • Document and share successful models of peer-led practice by people with lived experience of hepatitis B and hepatitis C in community hepatitis organisations